로딩 중...
52주 최고가 대비 69.4% 위치
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|
| 주요 재무실적 (USD) | ||||
| 매출액 | $31.69B | $31.23B | $32.36B | $33.54B |
| 영업이익 | $5.91B | $5.83B | $5.52B | $6.54B |
| 당기순이익 | $5.04B | $3.76B | $3.68B | $4.66B |
| 잉여현금흐름 (FCF) | $5.98B | $4.58B | $5.20B | $5.18B |
| 수익성 비율 | ||||
| 영업이익률 | 18.6% | 18.7% | 17.1% | 19.5% |
| 순이익률 | 15.9% | 12.0% | 11.4% | 13.9% |
| ROE (자기자본이익률) | 9.6% | 7.3% | 7.3% | 9.7% |
| ROA (자산이익률) | 5.5% | 4.1% | 4.1% | 5.1% |
| 성장성 비율 | ||||
| 매출 성장률 (YoY) | - | -1.4% | 3.6% | 3.6% |
| EPS 성장률 (YoY) | - | -24.4% | -2.1% | 30.8% |
| 투자 지표 & 가치배수 | ||||
| PER (주가수익배수) | 23.6x | 26.6x | 27.6x | 22.3x |
| PBR (주가순자산배수) | 2.1x | 1.9x | 2.0x | 2.2x |
| PSR (주가매출배수) | 3.6x | 3.1x | 3.0x | 3.1x |
| FCF Yield | 5.3% | 4.8% | 5.3% | 5.0% |
| 재무 건전성 (안정성) | ||||
| 부채비율 (D/E) | 0.46 | 0.47 | 0.50 | 0.59 |
| 유동비율 | 1.86 | 2.39 | 2.03 | 1.85 |
MOLINA HEALTHCARE INC
$179.86
$9.4B